Ephrin type-B receptor 2 – amyloid-beta oligomer interface (EphB2–AβO interface)

Ephrin type-B receptor 2 (EphB2) is a receptor tyrosine kinase that plays a pivotal role in the central nervous system by regulating synaptic plasticity and the trafficking of NMDA-type glutamate receptors (Cissé et al., 2011, Nature). In the context of Alzheimer's disease, soluble amyloid-beta (Aβ) oligomers bind with high affinity to the extracellular fibronectin type III domain of EphB2 (Mikulca et al., 2014, Frontiers in Aging Neuroscience). This pathological interaction triggers the internalization and proteasomal degradation of EphB2, leading to a significant reduction in its surface expression at the synapse. The loss of EphB2 disrupts NMDA receptor stability, resulting in impaired long-term potentiation and cognitive deficits characteristic of early-stage Alzheimer's (Lacor et al., 2007, Journal of Neuroscience). Targeting the EphB2–Aβ oligomer interface aims to prevent this degradation, thereby preserving synaptic integrity and cognitive function. Therapeutic strategies include the use of decoy receptors, small molecule inhibitors of the binding interface, or gene therapy to restore EphB2 levels (Stock et al., 2020, Journal of Biological Chemistry). Because EphB2 is also involved in axon guidance and vascular integrity, therapeutic interventions must specifically target the Aβ-binding site to avoid disrupting essential physiological signaling (Nievergall et al., 2012, Cellular and Molecular Life Sciences).

Other names

EphB2-Aβ interactionEphB2-AβO complexEphrin type-B receptor 2-amyloid beta interactionEphB2-Abeta oligomer interface

Inhibition of amyloid-beta oligomer binding to the fibronectin type III domain of the EphB2 extracellular region to prevent receptor internalization and proteasomal degradation, thereby maintaining NMDA receptor surface expression and synaptic function.